Study wrapper · #936
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
Chan ZH, Omar AS, Gill K, et al. Cardiology in review. 2026.
DOI: 10.1097/crd.0000000000001209PubMed: 41711462
Editor's note
This systematic review and meta-analysis pools ten randomized controlled trials with over three thousand participants, giving it strong evidentiary weight. The pooled incretin polyagonists, including tirzepatide and retatrutide, were associated with significant reductions in weight, waist circumference, HbA1c, and fasting glucose, but higher rates of gastrointestinal and hypoglycemic events. Serious adverse events did not differ significantly from placebo.
Plain-language abstract
A meta-analysis of randomized trials found incretin dual and triple agonists including tirzepatide and retatrutide were associated with significant weight loss and better metabolic markers, alongside more gastrointestinal side effects.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026